Cookie Consent by Privacy Policies website

Press Releases

Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange

November 4, 2024
View More

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity

October 22, 2024
View More

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity

October 21, 2024
View More

Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock

October 4, 2024
View More

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations

October 3, 2024
View More

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Launch of Clinical Study Combining Its Flagship Topical Exosome Skincare Products with a Medical Aesthetic Energy Device

October 2, 2024
View More

Elevai Labs Inc. Announces Pricing of $8.0 Million Public Offering

September 23, 2024
View More

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Results for E-Series Exosome Technology in Potential Melasma Applications

September 10, 2024
View More

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Encouraging Data Results Indicating Potential for Hair Restoration Using Proprietary Exosome Technology

September 3, 2024
View More

Elevai Labs Inc. Files Combination Patents with Yuva Biosciences for Breakthrough Hair and Scalp Care Technology Utilizing YuvaBioⓇ Y100™ Mitochondrial Innovation and Elevai Exosomes™

August 28, 2024
View More

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Data Results with Completion of Clinical Study of Elevai Enfinity™ Topical Exosome Serum

August 26, 2024
View More

Elevai Labs Inc. Subsidiary, Elevai Research Inc., Announces Preliminary Positive Research Data Highlighting the Potential of Proprietary Exosome Technology for Skin Health Applications

August 19, 2024
View More

Elevai Labs Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

August 14, 2024
View More

Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD

July 30, 2024
View More

Elevai Labs Inc. Subsidiary, Elevai Skincare, Announces The Elevai S-Series Hair and Scalp Care Product Line

June 28, 2024
View More

Elevai Labs Inc. Subsidiary, Elevai Skincare to Debut Upcoming New Product Line at The Aesthetic Show 2024

June 26, 2024
View More

Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs

June 14, 2024
View More

Elevai Labs Subsidiary, Elevai Skincare, to Present at the Beauty Through Science Conference in Stockholm

May 29, 2024
View More

Elevai Labs Inc Subsidiary, Elevai Biosciences, to Present at the UCLA LA-BEST 2024 Conference

May 22, 2024
View More

Elevai Labs Inc. Reports First Quarter 2024 Financial Results

May 15, 2024
View More

Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity

May 2, 2024
View More

Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome Skincare

May 1, 2024
View More

Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments

May 1, 2024
View More

Elevai Labs Highlights Global Distribution Partnership Overview: Contracts May Secure $4.9M Top Line Revenue Commitments

April 29, 2024
View More

ELEVAI Labs Enters the Taiwan Market with Signing of 5th International Distribution Agreement in 14 Months

April 22, 2024
View More

Elevai Labs Inc. Reports Record Full Year 2023 and Fourth Quarter Financial Results

March 29, 2024
View More

Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market

March 18, 2024
View More

ELEVAI Labs Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office

January 24, 2024
View More

ELEVAI LABS, Inc. Reports Strong Preliminary Unaudited Financial Performance for Fiscal Year 2023, Highlighting Significant Revenue Growth and Expanding Global Reach

January 17, 2024
View More

ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology

January 16, 2024
View More

ELEVAI LABS, Inc. to Participate in Upcoming Aesthetic Industry Conferences

January 2, 2024
View More

Elevai Labs Inc Announces Financial Results for the Quarter Ended September 30, 2023

December 11, 2023
View More

ELEVAI Labs, Inc. Expands International Distribution into Europe

December 7, 2023
View More

Elevai Labs Enters into Licensing Agreement with Yuva Biosciences to Combine Exosome and Mitochondrial Technologies to Develop New Aesthetics Products

November 29, 2023
View More

Univest Securities, LLC Announces Closing of $6 Million Initial Public Offering of Common Stock for its Client ELEVAI Labs Inc. (Nasdaq: ELAB)

November 24, 2023
View More

ELEVAI Labs, Inc. Announces Closing of $6,000,000 Initial Public Offering

November 24, 2023
View More

ELEVAI Labs Partners with Dmark Multisales Corporation as Exclusive Philippines Distributor

August 1, 2023
View More

ELEVAI Labs Announces New International Distributor Agreement with Central Circle Company in Kuwait Patented Exosome Skincare Line Now Available in the MENA Region

June 8, 2023
View More

ELEVAI LABS AMPLIFIES INTERNATIONAL REACH THROUGH VIET CAN TRADING AND SERVICE CO., LTD. WITH DISTRIBUTION IN VIETNAM

May 18, 2023
View More

ELEVAI Labs Announces Research Grant Award and Partnership to Better Characterize the ’Payload’ of ELEVAI's Stem Cell-derived Exosomes

April 26, 2023
View More

ELEVAI BRINGS PARADIGM-SHIFTING PROCEDURE SKINCARE TO ASLMS Company Unveils Groundbreaking Approach to Pre- and Post-Procedure Skincare

April 5, 2023
View More

ELEVAI LABS EXPANDS INTERNATIONAL REACH WITH INDUSTRY LEADER EVOLVE MEDICAL INC. FOR CANADIAN DISTRIBUTION

February 21, 2023
View More

ELEVAI LABS EXPANDS BOARD OF DIRECTORS WITH THE APPOINTMENT OF GLOBAL AESTHETICS EXECUTIVE CRYSTAL MUILENBURG

February 7, 2023
View More

ELEVAI LABS RETURNS TO INDUSTRY-LEADING OCTANE AESTHETICS TECH FORUM “People’s Choice Award” Winner Presents Groundbreaking Exosome Technology

January 17, 2023
View More

ELEVAI Labs, Inc. expands advisory board with the addition of James R. Headley as Strategic Advisor

November 29, 2022
View More

ELEVAI LABS EXPANDS ADVISORY BOARD WITH THE ADDITION OF JAMES R. HEADLEY AS STRATEGIC ADVISOR

November 29, 2022
View More

ELEVAI Labs, Inc. unveils paradigm shift skincare technology during Global Aesthetics ConferenceELEVAI Labs, Inc. unveils paradigm shift skincare technology during Global Aesthetics Conference

November 1, 2022
View More

ELEVAI Labs, Inc. announces laboratory expansion allowing fivefold increase in product manufacturing capabilities

September 22, 2022
View More

ELEVAI Labs, Inc. Announces appointment of Chris Kraneiss as Chief Commercial Officer

August 17, 2022
View More

ELEVAI Labs, Inc. is pleased to announce the appointment of Brenda Buechler as Chief Marketing and Brand Advisor

April 29, 2022
View More

ELEVAI is pleased to announce it has won the Peoples Choice Award at the 2022 Octane Aesthetics Tech Summit

January 25, 2022
View More

ELEVAI Labs, Inc. Announces Global Distribution Partnership With Premier Aesthetic Device Company Dermapenworld

January 21, 2022
View More

2022 Aesthetics Tech Summit in Newport Beach, California

January 6, 2022
View More

E-SERIES Product Line Launching

December 21, 2021
View More